DHR logo

Danaher Corporation Stock Price

NYSE:DHR Community·US$136.4b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 141 Fair Values set on narratives written by author

DHR Share Price Performance

US$190.48
-10.62 (-5.28%)
US$242.35
Fair Value
US$190.48
-10.62 (-5.28%)
21.4% undervalued intrinsic discount
US$242.35
Fair Value
Price US$190.48
AnalystConsensusTarget US$242.35

DHR Community Narratives

·
Fair Value US$242.35 21.4% undervalued intrinsic discount

DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds

0users have liked this narrative
0users have commented on this narrative
69users have followed this narrative

Trending Discussion

Updated Narratives

DHR logo

DHR: Bioprocess Recovery And Masimo Integration Will Support Premium Multiple

Fair Value: US$242.35 21.4% undervalued intrinsic discount
69 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet and good value.

0 Risks
3 Rewards

Danaher Corporation Key Details

US$24.8b

Revenue

US$10.2b

Cost of Revenue

US$14.6b

Gross Profit

US$10.9b

Other Expenses

US$3.7b

Earnings

Last Reported Earnings
Mar 27, 2026
Next Reporting Earnings
Jul 21, 2026
5.19
58.99%
14.83%
34.9%
View Full Analysis

About DHR

Founded
1969
Employees
59000
CEO
Rainer Blair
WebsiteView website
www.danaher.com

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Recent DHR News & Updates

Seeking Alpha Jun 29

Danaher: Why I'm Not Paying 24x P/E For 8% EPS Growth

Summary Danaher (DHR) is a high-quality life sciences holding company, but current valuation does not justify a buy. DHR's reliance on M&A and exposure to pharma spending cycles pose risks, with organic growth slowing to just above 4% AEPS in 2025. Despite a robust business system and strong integration track record, I see growth likely in the 4-7% range, insufficient for a 24-28x P/E. I rate DHR a 'HOLD' with a $140/share target, awaiting a more attractive entry point for market-beating upside. Read the full article on Seeking Alpha
Narrative Update Jun 26

DHR: Bioprocess Recovery And Masimo Integration Will Support Premium Multiple

Danaher’s analyst price target has been reduced by about $5 to $242, as analysts factor in a slightly higher discount rate, a more conservative profit margin, and updated views on life science tools demand that balance cautious sector sentiment with selective signs of recovery. Analyst Commentary Recent research around Danaher points to a mixed setup, with some analysts focusing on recovery potential in life science tools and bioprocessing, and others highlighting valuation questions and business complexity.

Recent updates

No updates